Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-3_10-cv-00482/USCOURTS-cand-3_10-cv-00482-1/pdf.json

Nature of Suit Code: 830
Nature of Suit: Patent
Cause of Action: 35:271 Patent Infringement

---

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-1- Case No. 3:10-cv-00482 (CRB)

AIA’S AND ELAN’S STIPULATED REQUEST FOR EXTENSION

DM_US:23374758_1 

BRYAN CAVE LLP

Robert Padway (Bar No. 48439) 

Berrie Goldman (Bar No. 246061) 

K. Lee Marshall, pro hac vice 

Ameer Gado, pro hac vice

Two Embarcadero Center, Suite 1400 

San Francisco, CA 94111 

Telephone: (415) 675-3400 

Facsimile: (415) 675-3434 

Attorneys for Plaintiff ALZHEIMER’S INSTITUTE OF AMERICA, INC. 

HOWREY LLP

Lloyd R. Day, Jr. (Bar No. 90875)

Jackie N. Nakamura (Bar No. 148531)

1950 University Avenue, 4th Floor 

East Palo Alto, California 94303 

Telephone: (650) 798-3500 

Facsimile: (650) 798-3600 

Attorneys for Defendant ELAN PHARMACEUTICALS, INC. 

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

SAN FRANCISCO DIVISION 

ALZHEIMER’S INSTITUTE OF AMERICA, 

INC., 

Plaintiff, 

vs. 

ELAN PHARMACEUTICALS, INC., 

ELI LILLY AND COMPANY, ANASPEC INC., 

IMMUNO-BIOLOGICAL LABORATORIES, 

INC., THE JACKSON LABORATORY, 

PHOENIX PHARMACEUTICALS, INC., and 

AMERICAN PEPTIDE COMPANY, INC., 

Defendants. 

ELAN PHARMACEUTICALS, INC., 

Counterclaim Plaintiff, 

vs. 

ALZHEIMER’S INSTITUTE OF AMERICA, 

INC., MICHAEL J. MULLAN, RONALD E. 

SEXTON, 

Counterclaim Defendants. 

Case No. 3:10-CV-00482 (CRB) 

ALZHEIMER’S INSTITUTE OF 

AMERICA, INC. AND ELAN 

PHARMACEUTICALS, INC.’S 

STIPULATED REQUEST FOR 

EXTENSION OF CASE MANAGEMENT 

CONFERENCE AND EXTENSION OF 

TIME FOR AIA’S ANSWER; 

DECLARATION OF JACKIE 

NAKAMURA IN SUPPORT OF 

STIPULATED REQUEST; AND 

[PROPOSED] ORDER 

DEMAND FOR JURY TRIAL 

Hon. Charles R. Breyer 

Case 3:10-cv-00482-EDL Document 84 Filed 07/29/10 Page 1 of 9
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-2- Case No. 3:10-cv-00482 (CRB)

AIA’S AND ELAN’S STIPULATED REQUEST FOR EXTENSION

DM_US:23374758_1 

In the interest of judicial economy as explained below, and pursuant to Civil L.R. 6-3, Plaintiff 

Alzheimer’s Institute of America, Inc. (“AIA”) and Defendant and Counterclaim Plaintiff Elan 

Pharmaceuticals, Inc. (“Elan Pharmaceuticals”) file this stipulated request for: (1) an extension of 30 

days for AIA, Dr. Michael Mullan and Mr. Ronald Sexton to respond to Elan Pharmaceutical’s 

counterclaims (each Counterclaim Defendant shall file a response on or before September 15, 2010); 

(2) a continuance of the initial Case Management Conference (“CMC”) to October 22, 2010, or as 

soon thereafter as the Court’s calendar will allow; (3) continuation of the parties’ corresponding 

obligations to meet and confer in advance of the CMC regarding initial disclosures and a Case 

Management Statement, and (4) continuance of the parties’ deadline for filing a Joint Case 

Management Statement. All other defendants agree with the request or do not oppose it. 

This patent infringement case involves four patents and multiple defendants. In its Answer, 

Elan Pharmaceuticals has counterclaimed against AIA and named two new Counterclaim Defendants, 

Dr. Michael Mullan and Mr. Ronald Sexton (served July 26 and 27, 2010, respectively). 

This Court had previously scheduled a Case Management Conference for May 14, 2010, which 

was ordered by stipulation to the currently scheduled date of August 13, 2010. Other than the Case 

Management Conference, no other scheduled hearings will be affected by this extension. 

AIA and Elan Pharmaceuticals request and stipulate to, and no party opposes, these extensions 

of time. 

If the Court grants this stipulated request, the following dates would then apply: 

1. Each Counterclaim defendant has a 30-day extension to respond to Elan 

Pharmaceuticals’ Counterclaim and shall file a response on or before September 15, 

2010; 

2. The Case Management Conference will be continued to October 22, 2010, at 8:30 a.m., 

or thereafter, at the convenience of the Court; 

3. September 16, 2010 is the parties’ last day to meet and confer regarding initial 

disclosures (since this will be the parties’ Rule 26(f) conference, the Rule 26(a) Initial 

Disclosures and Rule 26(f) Report/Discovery Plan shall be due by September 30, 2010); 

4. October 15, 2010 is the parties’ last day to file a Joint Case Management Statement; and 

Case 3:10-cv-00482-EDL Document 84 Filed 07/29/10 Page 2 of 9
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-3- Case No. 3:10-cv-00482 (CRB)

AIA’S AND ELAN’S STIPULATED REQUEST FOR EXTENSION

DM_US:23374758_1 

5. Pursuant to Local Rule 16-10(a) and this Court’s Standing Order, defendant The 

Jackson Laboratory’s counsel, Michael N. Rader and/or Chelsea A. Loughran, may 

appear by telephone at the Initial Case Management Conference. 

Dated: July 28, 2010 

Respectfully submitted, 

BRYAN CAVE LLP

By: /s/ Berrie R. Goldman 

Robert Padway (Bar No. 48439_ 

Berrie Goldman (Bar No. 246061) 

K. Lee Marshall, pro hac vice 

Ameer Gado, pro hac vice

Bryan Cave LLP 

Two Embarcadero Center, Suite 1400 

San Francisco, CA 94111 

Attorneys for Plaintiff 

Alzheimer’s Institute of America, Inc. 

 HOWREY LLP

By: /s/ Jackie N. Nakamura 

Lloyd R. Day, Jr. (Bar No. 90875) 

Jackie N. Nakamura (Bar No. 148531) 

HOWREY LLP 

1950 University Avenue, 4th Floor 

East Palo Alto, California 94303 

Telephone: (650) 798-3500 

Facsimile: (650) 798-3600 

Attorneys for Defendant 

ELAN PHARMACEUTICALS, INC. 

Case 3:10-cv-00482-EDL Document 84 Filed 07/29/10 Page 3 of 9
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-4- Case No. 3:10-cv-00482 (CRB)

AIA’S AND ELAN’S STIPULATED REQUEST FOR EXTENSION

DM_US:23374758_1 

DECLARATION OF JACKIE NAKAMURA IN SUPPORT OF STIPULATED REQUEST 

I, Jackie N. Nakamura, declare as follows: 

1. I am an attorney licensed to practice before this Court and all courts of the State of 

California. I am a partner with Howrey LLP, counsel for Elan Pharmaceuticals, Inc. (“Elan 

Pharmaceuticals”) in the above-referenced action. 

2. The contents of this declaration are based upon my personal knowledge and are true and 

correct to the best of my knowledge and belief. If called to testify, I could and would testify thereto. 

3. The contents of the foregoing Stipulated Request are true and correct to the best of my 

knowledge and belief 

4. Plaintiff’s counsel and all counsel for co-Defendants have stipulated to, or do not 

oppose, these requested extensions of time. 

5. This Court had previously scheduled a Case Management Conference for May 14, 

2010, which was ordered by stipulation to the currently scheduled date of August 13, 2010. 

6. Other than the Case Management Conference, no other scheduled hearings will be 

affected by this extension. 

I declare under penalty of perjury under the laws of the United States that the foregoing is true 

and correct. 

Dated: July 28, 2010 

By: /s/ Jackie Nakamura 

 Jackie N. Nakamura 

Case 3:10-cv-00482-EDL Document 84 Filed 07/29/10 Page 4 of 9
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-5- Case No. 3:10-cv-00482 (CRB)

AIA’S AND ELAN’S STIPULATED REQUEST FOR EXTENSION

DM_US:23374758_1 

[PROPOSED] ORDER 

FOR GOOD CAUSE SHOWN, IT IS HEREBY ORDERED that Alzheimer’s Institute of 

America’s and Elan Pharmaceuticals, Inc.’s Stipulated Request is GRANTED. 

1. Each Counterclaim defendant has a 30-day extension to respond to Elan 

Pharmaceuticals’ Counterclaim and shall file a response on or before September 15, 

2010; 

2. The Case Management Conference will be continued to October 22, 2010, at 8:30 a.m., 

or thereafter, at the convenience of the Court; 

3. September 16, 2010 is the parties’ last day to meet and confer regarding initial 

disclosures (since this will be the parties’ Rule 26(f) conference, the Rule 26(a) Initial 

Disclosures and Rule 26(f) Report/Discovery Plan shall be due by September 30, 2010); 

4. October 15, 2010 is the parties’ last day to file a Joint Case Management Statement; and 

5. Pursuant to Local Rule 16-10(a) and this Court’s Standing Order, defendant The 

Jackson Laboratory’s counsel, Michael N. Rader and/or Chelsea A. Loughran, may 

appear by telephone at the Initial Case Management Conference. 

PURSUANT TO STIPULATION, IT IS SO ORDERED. 

Dated 

Hon. Charles R. Breyer 

U.S. District Court Judge 

Case 3:10-cv-00482-EDL Document 84 Filed 07/29/10 Page 5 of 9
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-1- Case No. 3:10-cv-00482 (CRB)

AIA’S AND ELAN’S STIPULATED REQUEST FOR EXTENSION

DM_US:23374758_1 

PROOF OF SERVICE

I am employed in the County of San Mateo, State of California. I am over the age of 18 and 

not a party to the within Action. My business address is 1950 University Avenue, 4th Floor, East Palo 

Alto, California 94303. 

On July 28, 2010, I served on the interested parties in said Action the within: 

1. ALZHEIMER’S INSTITUTE OF AMERICA, INC.’S AND ELAN 

PHARMACEUTICALS, INC.’S STIPULATED REQUEST FOR EXTENSION 

OF CASE MANAGEMENT CONFERENCE AND EXTENSION OF TIME FOR 

AIA’S ANSWER; 

2. DECLARATION OF JACKIE NAKAMURA IN SUPPORT OF STIPULATED 

REQUEST; AND 

3. [PROPOSED] ORDER

I hereby certify that a copy of the foregoing document was filed electronically in compliance 

with Civil Local Rule 5-4 and General Order 45. Therefore, per Civil Local Rule 5-5(b) and General 

Order 45 § IX, this document was served on all counsel who are deemed to have consented to 

electronic service. All counsel of record not deemed to have consented to electronic service were 

served with a true and correct copy of this document as indicated below. 

Robert Padway 

Berrie Goldman 

Bryan Cave LLP 

Two Embarcadero Center, Suite 1400 

San Francisco, CA 94111 

robert.padway@bryancave.com 

berrie.goldman@bryancave.com 

Attorneys for Plaintiff 

Alzheimer’s Institute of America, Inc. 

K. Lee Marshall

Ameer Gado

Bryan Cave LLP 

One Metropolitan Square 

211 North Broadway, Suite 3600 

St. Louis, MO 63102-2750 

klmarshall@bryancave.com 

aagado@bryancave.com 

Attorneys for Plaintiff 

Alzheimer’s Institute of America, Inc. 

David Godkin 

American Peptide Co., Inc. 

777 E. Evelyn Avenue 

Sunnyvale, CA 94086 

david@americanpeptide.com 

Attorney for Defendant 

American Peptide Co., Inc. 

Bruce Charles Piontkowski 

Tingley Piontkowski LLP

10 Almaden Boulevard, Suite 430 

San Jose, CA 95113 

bpiontkowski@tingleyllp.com 

Attorneys for Defendant 

American Peptide Co., Inc. 

Case 3:10-cv-00482-EDL Document 84 Filed 07/29/10 Page 6 of 9
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-2- Case No. 3:10-cv-00482 (CRB)

AIA’S AND ELAN’S STIPULATED REQUEST FOR EXTENSION

DM_US:23374758_1 

Albert Hong 

AnaSpec, Inc. 

34801 Campus Drive 

Fremont, CA 94555 

albertoh@anaspec.com 

Attorney for Defendant 

AnaSpec Incorporated 

Jeffrey McKinney 

McKinney Law Group APC. 

851 Moraga Road, Bungalow B 

Lafayette, CA 94549 

jeffrey@mckinneylawgroup.com 

Attorneys for Defendant 

AnaSpec Incorporated 

Manisha Desai, pro hac vice

Eli Lilly and Company 

Lilly Corporate Center 

Indianapolis, IN 46285 

Attorney for Defendant 

Eli Lilly and Company 

Robert F. McCauley III 

Finnegan, Henderson, Farabow, 

Garrett & Dunner, LLP 

3300 Hillview Avenue 

Palo Alto, CA 94304-1203 

robert.mccauley@finnegan.com 

Attorneys for Defendant 

Eli Lilly and Company 

Robert Shaffer, pro hac vice 

Laura Masurovsky, pro hac vice 

Robert Bajefsky, pro hac vice 

Amy Purcell, pro hac vice 

Finnegan, Henderson, Farabow, 

Garrett & Dunner, LLP 

901 New York Avenue, NW 

Washington, DC 20001-4413 

robert.shaffer@finnegan.com 

laura.masurovsky@finnegan.com 

robert.bajefsky@finnegan.com 

amy.purcell@finnegan.com 

Attorneys for Defendant 

Eli Lilly and Company 

Charles Lipsey, pro hac vice 

L. Scott Burwell, pro hac vice

Finnegan, Henderson, Farabow, 

Garrett & Dunner, LLP 

Two Freedom Square 

11955 Freedom Drive 

Reston, VA 20190-5675 

charles.lipsey@finnegan.com 

scott.burwell@finnegan.com 

Attorneys for Defendant 

Eli Lilly and Company 

Stephen Doyle, pro hac vice

Stephen Hance, pro hac vice

Doyle Hance Lawyers LLC 

Two Carlson Parkway, Suite 230 

Minneapolis, MN 55447-4466 

spd@doylehance.com 

swh@doylehance.com 

Attorneys for Defendant 

Immuno-Biological 

Laboratories, Incorporated 

Todd Noah 

Dergosits & Noah LLP 

Three Embarcadero Center, Suite 410 

San Francisco, CA 94111 

tnoah@dergnoah.com 

Attorneys for Defendant 

The Jackson Laboratory 

Case 3:10-cv-00482-EDL Document 84 Filed 07/29/10 Page 7 of 9
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-3- Case No. 3:10-cv-00482 (CRB)

AIA’S AND ELAN’S STIPULATED REQUEST FOR EXTENSION

DM_US:23374758_1 

Michael Rader 

Chelsea Loughran, pro hac vice

Wolf, Greenfield & Sacks, P.C. 

600 Atlantic Avenue 

Boston, MA 02210-2206 

mrader@wolfgreenfield.com 

cloughran@wolfgreenfield.com 

Attorneys for Defendant 

The Jackson Laboratory 

Eng Tau 

Phoenix Pharmaceuticals, Inc. 

330 Beach Road 

Burlingame, CA 94010 

engtau@phoenixpeptide.com 

Attorney for Defendant 

Phoenix Pharmaceuticals, Inc. 

(EMAIL/ELECTRONIC TRANSMISSION) Based on a court order or an agreement of the 

parties to accept service by e-mail or electronic transmission, I caused the documents to be sent 

to the persons at the e-mail addresses listed above. I did not receive, within a reasonable time 

after the submission, any electronic message or other indication that the transmission was 

unsuccessful. 

I declare under penalty of perjury that I am employed in the office of a member of the bar of 

this Court at whose direction the service was made and that the foregoing is true and correct. 

Executed on July 28, 2010, at East Palo Alto, California. 

/s/ Jackie Nakamura 

 Jackie Nakamura 

X 

Case 3:10-cv-00482-EDL Document 84 Filed 07/29/10 Page 8 of 9
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-5- Case No. 3:10-cv-00482 (CRB)

AIA’S AND ELAN’S STIPULATED REQUEST FOR EXTENSION

DM_US:23374758_1 

[PROPOSED] ORDER 

FOR GOOD CAUSE SHOWN, IT IS HEREBY ORDERED that Alzheimer’s Institute of 

America’s and Elan Pharmaceuticals, Inc.’s Stipulated Request is GRANTED. 

1. Each Counterclaim defendant has a 30-day extension to respond to Elan 

Pharmaceuticals’ Counterclaim and shall file a response on or before September 15, 

2010; 

2. The Case Management Conference will be continued to October 22, 2010, at 8:30 a.m., 

or thereafter, at the convenience of the Court; 

3. September 16, 2010 is the parties’ last day to meet and confer regarding initial 

disclosures (since this will be the parties’ Rule 26(f) conference, the Rule 26(a) Initial 

Disclosures and Rule 26(f) Report/Discovery Plan shall be due by September 30, 2010); 

4. October 15, 2010 is the parties’ last day to file a Joint Case Management Statement; and 

5. Pursuant to Local Rule 16-10(a) and this Court’s Standing Order, defendant The 

Jackson Laboratory’s counsel, Michael N. Rader and/or Chelsea A. Loughran, may 

appear by telephone at the Initial Case Management Conference. 

PURSUANT TO STIPULATION, IT IS SO ORDERED. 

Dated 

Hon. Charles R. Breyer 

U.S. District Court Judge 

July 29, 2010

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORN

I

A

IT IS SO ORDERED

Judge Charles R. Breyer

Case 3:10-cv-00482-EDL Document 84 Filed 07/29/10 Page 9 of 9